

References

1- Abbott KC, Bucci JR, Matsumoto CS, et al(2003) : Hepatitis C and renal transplantation in the era of modern immunosuppression. J Am Soc Nephrol , 14: 2908.

2-Abbott KC, Lentine KL, Bucci JR, et al(2004): Impact of diabetes and hepatitis after kidney transplantation on patients who are affected by hepatitis C virus. J Am Soc Nephrol, 15: 3166.

3-Abdoul H, Mallet V, Pol S, Fontanet A.(2008): Serum alpha-fetoprotein predicts treatment outcome in chronic hepatitis C patients regardless of HCV genotype. PLoS One. 11;3(6):e2391.

4-Ackerman Z, Pappo O, Ben-Dov IZ.(2011): The prognostic value of changes in serum ferritin levels during therapy for hepatitis C virus infection. J Med Virol. , 83(7):1262-8.

5- Ahmad A., Hasan F., Abdeen S. et al.(2004): “Transjugular liver biopsy in patients with end-stage renal disease,” Journal of Vascular and Interventional Radiology,. 15,. 3, 257–260.

6- Alberti A. et al.(2001): “Outcome of initially mild chronic hepatitis C,” Hepatology,. 34, 225 A .

7-Alberti A.(2009): What are the comorbidities influencing the management of patients and the response to therapy in chronic hepatitis C? *Liver Int*, 29: 15–8.

8-Alric L, Di-Marino V, Selves J, et al(2002): Long-term impact of renal transplantation on liver fibrosis during hepatitis C virus infection. *Gastroenterology* , 123: 1494.

9-Alter HJ.(2005): HCV natural history: the retrospective and prospective in perspective. *J Hepatol*, 43:550-552.

10-Alvarez-Uria G, Day JN, Nasir AJ, et al(2009): Factors associated with treatment failure of patients with psychiatric diseases and injecting drug users in the treatment of genotype 2 or 3 hepatitis C chronic infection. *Liver Int*, 29: 1051–5.

11-Anonymous, (1999):“Global surveillance and control of hepatitis C,” *Journal of Viral Hepatitis*, 6, 1, 35–47.

12-Asselah T, Benhamou Y, Marcellin P.(2009): Protease and polymerase inhibitors for the treatment of hepatitis C. *Liver Int*, 29: 57–67.

13-Asselah T, Bieche I, Narguet S, et al.(2008): Liver gene expression signature to predict response to pegylated interferon plus ribavirin combination therapy in patients with chronic hepatitis C. *Gut*, 57: 516–24.

14-Asselah T, Estrabaud E, Bieche I, Lapalus M, De Muynck S, Vidaud M, Saadoun D, Soumelis V, Marcellin P.(2010): Hepatitis C: viral and host factors associated with non-response to pegylated interferon plus ribavirin. *Liver Int.* 30(9):1259-69.

15-Asselah T, Martinot M, Cazals-Hatem D, et al(2002): Hypervariable region 1 quasispecies in hepatitis C virus genotypes 1b and 3 infected patients with normal and abnormal alanine aminotransferase levels. *J Viral Hepat*, 9: 29–35.

16-Aurora R, Donlin MJ, Cannon NA, et al(2009): Genome-wide hepatitis C virus amino acid covariance networks can predict response to antiviral therapy in humans. *J Clin Invest*, 119: 225–36.

17-Baid S, Pascual M, Williams Jr WW, et al(1999): Renal thrombotic microangiopathy associated with anticardiolipin antibodies in hepatitis C positive allograft recipients. *J Am Soc Nephrol*, 10: 146.

18-Bain VG, Kaita KD, Marotta P, et al(2008): Safety and antiviral activity of albinterferon alfa-2b dosed every four weeks in genotype 2/3 chronic hepatitis C patients. *Clin Gastroenterol Hepatol*, 6 : 701 - 06

19-Bain VG, Kaita KD, Yoshida EM, et al(2006): A phase 2 study to evaluate the antiviral activity, safety, and pharmacokinetics of recombinant human albumin-interferon alfa fusion protein in genotype 1 chronic hepatitis C patients. *J Hepatol*, 44 : 671 -78

20-Baldo V, Baldovin T, Trivello R, Floreani A(2008):

Epidemiology of HCV infection. Curr Pharm Des,14(17):1646-54.

21-Bedossa P and Poynard T(1996):“An algorithm for the grading of activity in chronic hepatitis C,” Hepatology, 24, 2, 289–293.

22-Bedossa P, Poynard T.(1996): An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology ,24(2):289-93.

23-Berenguer M.(2008): Treatment of chronic hepatitis C in hemodialysis patients. Hepatology, 48: 1690.

24-Bestard O, Cruzado JM, Ercilla G, et al(2006): Rituximab induces regression of hepatitis C virus-related membranoproliferative glomerulonephritis in renal allograft. Nephrol Dial Transplant, 21: 2320.

25-Blight, K. J., Kolykhalov, A. A. and Rice, C. M. (2000): Efficient initiation of HCV RNA replication in cell culture. Science 290, 1972–1974.

26-Bloom RD, Lake JR.(2006): Emerging issues in hepatitis C virus positive liver and kidney transplant recipients. Am J Transplant, 6: 2232.

- 27-Bloom RD, Rao V, Weng F, et al.(2002):** Association of hepatitis C with posttransplant diabetes en renal transplant patients on tacrolimus. J Am Soc Nephrol, 13: 1374.
- 28-Bloom RD, Sayer G, Fa K, et al.(2005):** Outcome of hepatitis C virus-infected kidney transplant candidates who remain on the waiting list. Am J Transplant, 5: 139.
- 29-Bostan N, Mahmood T.(2010):** An overview about hepatitis C: a devastating virus. Crit Rev Microbiol,36(2):91-133.
- 30-Breitenfeldt MK, Rasenak J, Berthold H, et al.(2003):** Impact of hepatitis B and C on graft loss and mortality of patients after renal transplantation. Clin Transplant, 21: 300.
- 31-Bruchfeld A, Wilczek H, Elinder CG.(2004):** Hepatitis C infection, time in renal-replacement therapy, and outcome after kidney transplantation. Transplantation,78(5):745-50.
- 32-Bruno S, Stroffolini T, Colombo M, Bollani S, Benvegna L, Mazzella G, et al.(2007):** Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology,45:579-587.
- 33-Burra P, Buda A, Livi U, et al.(2006):** Occurrence of post-transplant lymphoproliferative disorders among over thousand adult

recipients: any role for hepatitis C infection? Eur J Gastroenterol Hepatol, 18: 1065.

34-Butera D, Marukian S, Iwamaye AE, et al.(2005): Plasma chemokine levels correlate with the outcome of antiviral therapy in patients with hepatitis C. Blood, 106: 1175–82.

35-Caeiro F., V. Baptista V., N. Rodrigues N., D. Carvalho D., I. Aires I., F. Remédio F. and F. Nolasco A. (2011): Treatment of Hepatitis C Virus Infection in Kidney Transplant Recipients. Transplantation Proceedings, 43, 259–262.

36-Caillard S, Agodoa LY, Bohen EM, Abbott KC.(2006): Myeloma, Hodgkin disease and lymphoid leukaemia after renal transplantation: characteristics, risk factors and prognosis. Transplantation, 27: 888.

37-Caillard S, Lelong C, Pessione F, Moulin B.(2006): Post-transplant lymphoproliferative disorders occurring after renal transplantation in adults: report of 230 cases from the French Registry. Am J Transplant, 6: 2735.

38-Canbakan M., Senturk H., Canbakan B. et al.(2010): “Validation of biochemical markers for the prediction of liver fibrosis and necroinflammatory activity in hemodialysis patients

with chronic hepatitis C,” *Nephron—Clinical Practice*, 117, no. 3, c289–c295.

39-Chen L, Borozaan I, Feld J, et al.(2005): Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection. *Gastroenterology*, 128: 1437–44.

40-Chevaliez S, Pawlotsky JM.(2007): Interferon-based therapy of hepatitis C. *Adv Drug Deliv Rev* , 59 : 1222 -41

41-Cholongitas E, Papatheodoridis GV.(2008): Review article: novel therapeutic options for chronic hepatitis C. *Aliment Pharmacol Ther* , 27 : 866 -84

42-Choo, Q. L., Kuo, G., Weiner, A. J., Overby, L. R., Bradley, D. W. and Houghton, M. (1989): Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. *Science* 244, 359–362

43-Chung RT, Gale M Jr, Polyak SJ, Lemon SM, Liang TJ, Hoofnagle JH.(2008): Mechanisms of action of interferon and ribavirin in chronic hepatitis C: Summary of a workshop. *Hepatology*. ,47(1):306-20.

44-Corell A, Morales JM, Mandron~o A, et al.(1995): Immunosuppression induced by hepatitis C virus infection reduces acute renal transplant rejection. *Lancet*; 346: 1497.

45-Covic A, Abramowicz D, Bruchfeld A, et al.(2009):

Endorsement of the kidney disease improving global outcomes (KDIGO) hepatitis C guidelines: a european renal best practice (ERBP) position statement. *Nephrol Dial Transplant*, 24: 719.

46-Cruzado JM, Carrera M, Torras J, Grinyo JM.(2001):

Hepatitis C virus infection and de novo glomerular lesions in renal allografts. *Am J Transplant*, 1: 171.

47-Cruzado JM, Casanovas-Taltavull T, Torras J, Baliellas C, Gil-Vernet S, Grinyo´ JM.(2003): Pretransplant Interferon prevents hepatitis C virus-associated glomerulonephritis in renal allografts by HCV-RNA clearance. *Am J Transplant*, 3: 357.

48-Derbala M, Amer A, Bener A, Lopez AC, Omar M, El Ghannam M.(2005): Pegylated interferon-alpha 2b-ribavirin combination in Egyptian patients with genotype 4 chronic hepatitis. *J Viral Hepat* ,12(4):380-5.

49-Derbala MF, Amer AM, Almohanadi M, John A, Amin A, John A, Sharma M, Alkaabi SR, Al Dweik NZ, Pasic F, Yaqoob R, Butt MT, Shebl FM.(2010): Hepatitis C virus genotype 4 with normal transaminases: histological changes, schistosomiasis and response to treatment. *J Viral Hepat*. 25. doi: 10.1111/j.1365-2893.2010.01403.x. [Epub ahead of print].

50-Deuffic-Burban S, Deltenre P, Louvet A, Canva V, Dharancy S, Hollebecque A, et al.(2008): Impact of viral eradication on mortality related to hepatitis C: a modeling approach in France. J Hepatol,49:175-183.

51-Deutsch M, Hadziyannis SJ.(2008): Old and emerging therapies in chronic hepatitis C: an update. J Viral Hepat ,15: 2-11

52-Dominguez-Gil B, Esforzado N, Andres A, et al.(2009): Impact of induction with biologics in kidney transplant patients with a positive serology for hepatitis C: Long-term assessment in a collaborative study. Am J Transplant, 9 (Suppl 2): 282.

53-Dominguez-Gil B, Esforzado N, Campistol JM, Andre´s A, Morales JM.(2007): Use of hepatitis C–positive donors for kidney transplantation. Transplantation Reviews, 21: 195.

54-Dominguez-Gil B, Morales JM.(2009): Transplantation in the patient with hepatitis C. Transpl Int,22(12):1117-31.

55-Dominguez-Gil B, Morales JM.(. 2009): Transplantation in the patient with hepatitis C. Transpl Int,22(12):1117-31.

56-Durantel D, Alotte C, Zoulim F.(2007): Glucosidase inhibitors as antiviral agents for hepatitis B and C. Curr Opin Investig Drugs, 8 : 125 -9

57-Egyptian Ministry of Health.(2007): Egyptian Ministry of Health Annual Report.

58-Einollahi B, Alavian SM.(2010): Hepatitis C virus infection and kidney transplantation: a review for clinicians. Iran J Kidney Dis,4(1):1-8.

59-Elkady A, Tanaka Y, Kurbanov F, et al.(2009): Genetic variability of hepatitis C virus in South Egypt and its possible clinical implication. J Med Virol,81(6):1015-23.

60-El-Shamy A, Nagano-Fujii M, Sasase N, et al.(2008): Sequence variation in hepatitis C virus nonstructural protein 5A predicts clinical outcome of pegylated interferon/ribavirin combination therapy. Hepatology,48: 38–47.

61-Enomoto N, Sakuma I, Asahina Y, et al.(1996): Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med, 334: 77–81.

62-European Best Practice Guidelines for Renal Transplantation.(2000): Section I: Evaluation, selection and preparation of the potential recipient. Nephrol Dial Transplant; 15(Suppl. 7): 3.

63-F. Nicot, N. Kamar, B. Mariam´e, L. Rostaing, C. Pasquier, and J.(2010): Izopet, “No evidence of occult hepatitis C virus (HCV) infection in serum of HCV antibody-positive HCV RNA

negative kidney-transplant patients,” *Transplant International*, 23, 6, 594–601.

64-Fabrizi F, Bromberg J, Elli A, Dixit V, Martin P.(2005):
Review article: hepatitis C virus and calcineurin inhibition after renal transplantation. *Aliment Pharmacol Ther*,22(8):657-66.

65-Fabrizi F, Bromberg J, Elli A, Dixit V, Martin P.(2005):
Review article: hepatitis C virus and calcineurin inhibition after renal transplantation. *Aliment Pharmacol Ther*,22(8):657-66.

66-Fabrizi F, Lunghi G, Dixit V, martin P.(2006): Meta-analysis: antiviral therapy of hepatitis c virus-related liver disease in renal transplant patients. *Aliment Pharmacol Ther*, 24: 1413.

67-Fabrizi F, Lunghi G, Dixit V, Martin P.(2006):
Meta-analysis: anti-viral therapy of hepatitis C virus-related liver disease in renal transplant patients. *Aliment Pharmacol Ther*,24(10):1413-22.

68-Fabrizi F, Martin P, Dixit V, Bunnapradist S, Dulai G.(2005):
Hepatitis C virus antibody status and survival after renal transplantation: meta-analysis of observational studies. *Am J Transplant*, 5: 1452.

69-Fabrizi F, Messa P, Martin P, et al.(2008): Hepatitis C virus infection and post-transplant diabetes mellitus among renal transplant patients: a meta-analysis. *Int J Artif Organs*, 31: 675.

70-Fabrizi F, Poordad FF, Martin P (2002): Hepatitis C infection and the patient with end-stage renal disease. *Hepatology* 36:3.

71-Fabrizi F, Takkouche B, Lunghi G, Dixit, Messa VP, and Martin P.(2007): “The impact of hepatitis C virus infection on survival in dialysis patients: meta-analysis of observational studies,” *Journal of Viral Hepatitis*, 14, 10, 697–703.

72-Feinstone, S. M., Kapikian, A. Z., Purcell, R. H., Alter, H. J. and Holland, P. V. (1975): Transfusion-associated hepatitis not due to viral hepatitis type A or B. *N. Engl. J. Med.* 292, 767–770

73-Feld JJ, Hoofnagle JH.(2005): Mechanism of action of interferon and ribavirin in treatment of hepatitis C. *Nature*, 436:967-972.

74-Fellay J, Thompson AJ, Ge D, et al.(2010): ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. *Nature* 464: 405–8.

75-Finelli L, Miller JT., Tokars JL., and Arduino MJ.(2005): “National surveillance of dialysis-associated diseases in the United States, 2002,” *Seminars in Dialysis*, 18, no. 1, 52–61.

76-Fissell RB., Bragg-Gresham JL.(2004): and Woods JD. (2004): Patterns of hepatitis C prevalence and seroconversion in hemodialysis units from three continents: The DOPPS. *Kidney Int* 65:2335.

77-Flisiak R, Flisiak I.(2010): Albinterferon-alpha 2b: a new treatment option for hepatitis C. *Expert Opin Biol Ther*,10(10):1509-15.

78-Forman JP, Tolkoff-Rubin N, Pascual M, Lin J.(2004): Hepatitis C, acute humoral rejection, and renal allograft survival. *J Am Soc Nephrol* 15: 3249.

79-Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL, Jr., et al.(2002): Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. *N Engl J Med*,347:975-982.

80-Ge D, Fellay J, Thompson AJ, et al.(2009): Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. *Nature*, 461: 399–401.

81-Gentil MA, Rocha JL, Rodriguez-Algarra G, et al.(1999): Impaired kidney transplant survival in patients with antibodies to hepatitis C virus. *Nephrol Dial Transplant*, 14: 2455.

82-Ghafari A. and Sanadgol H. (2008): Impact of Hepatitis B and Hepatitis C Virus Infections on Patients and Allograft Outcomes in

Renal Transplant Recipients: A Single Center Study. Transplantation Proceedings, 40, 196–198.

83-Gish RG. Treating HCV with ribavirin analogues and ribavirin-like molecules.(2006): J Antimicrob Chemother ,57 : 8 -13

84-Glicklich D, Kapoian T.(1996): Should the hepatitis C positive end stage renal disease patient be transplanted? Seminar Dial, 9: 5.

85-Gonzalez E, Esforzado N, Usera G, et al.(2006): Long-term results of hepatitis C virus-associated glomerular lesions alter renal transplantation. Am J Transplant, Suppl 123 (abstract 167).

86-Goodkin DA., Bragg-Gresham JL., Koenig K. et al.(2003): “Association of comorbid conditions and mortality in hemodialysis patients in Europe, Japan, and the United States: the dialysis outcomes and practice patterns study (DOPPS),” Journal of the American Society of Nephrology, 14, 12, 3270–3277.

87-Gottwein, J. M., Scheel, T. K., Jensen, T. B., Lademann, J. B., Prentoe, J. C., Knudsen, M. L., Hoegh, A. M. and Bukh, J. (2009): Development and characterization of hepatitis C virus genotype 1–7 cell culture systems: Role of CD81 and scavenger receptor class B type I and effect of antiviral drugs. Hepatology 49, 364–377

88-H. Hinrichsen, G. Leimenstoll, G. Stegen, H.(2002): Schrader, U. R. Fölsch, and W. E. Schmidt, “Prevalence and risk factors of

hepatitis C virus infection in haemodialysis patients: a multicentre study in 2796 patients,” *Gut*, vol. 51, no. 3, pp. 429–433.

89-Habib M, Mohamed MK, Abdel-Aziz F, et al.(2001): Hepatitis C virus infection in a community in the Nile Delta: risk factors for seropositivity. *Hepatology*, 33:248-253.

90-Haem J, Berthoux P, Mosnier JF, et al.(1996): Clear evidence of the existence of healthy carriers of hepatitis C virus among renal transplant recipients. *Transplantation*, 62: 699.

91-Hernandez D, Sanchez-Fructuoso A, Gonzalez-Posada JM, Arias M, Campistol JM, Rufino M, et al.(2009): A novel risk score for mortality in renal transplant recipients beyond the first posttransplant year. *Transplantation*.;88(6):803-9.

92-Hestin D, Guillemin F, Castin N, et al.(1998): Pre-transplant hepatitis C virus infection: A predictor of proteinuria after renal transplantation. *Transplantation*, 65: 741.

93-Hestin D, Guillemin F, Castin N, et al.(1998): Pre-transplant hepatitis C virus infection: A predictor of proteinuria after renal transplantation. *Transplantation*, 65: 741.

94-Hezode C, Zafrani ES, Roudot-Thoraval F, et al.(2008): Daily cannabis use: a novel risk factor of steatosis severity in patients with chronic hepatitis C. *Gastroenterology*, 134: 432–9.

95-Hmajed F, Mamou MB., Saune-Sandres K. et al.(2006):

“Hepatitis C virus infection among dialysis patients in Tunisia: incidence and molecular evidence for nosocomial transmission,”
Journal of Medical Virology, 78, 2185–191.

96-Hoch B, Jucknevicius I, Liapis H.(2002): Glomerular injury associated with hepatitis C infection. A correlation with blood and tissue HCV_PCR. Semin Diag Pathol, 19: 175.

97-Hoffmann CJ, Subramanian AK, Cameron AM, Engels EA. (2008):Incidence and risk factors for hepatocellular carcinoma after solid organ transplantation. Transplantation, 86: 784.

98-Huang Y, Yang H, Borg BB, et al.(2007): A functional SNP of interferon-gamma gene is important for interferon-alpha-induced and spontaneous recovery from hepatitis C virus infection. Proc Natl Acad Sci USA, 104: 985–90.

99-Hwang Y, Chen EY, Gu ZJ, et al.(2006): Genetic predisposition of responsiveness to therapy for chronic hepatitis C. Pharmacogenomics, 7: 697–709.

100-Ibrahim M, Gomaa W, Ibrahim Y, El Hadad H, Shatat M, Aleem AA, Essawy M, Fouad YM.(2010): Nitric oxide levels and sustained virological response to pegylated-interferon alpha2a plus ribavirin in chronic HCV genotype 4 hepatitis: A prospective study. J Gastrointest Liver Dis. ,19(4):387-92.

101-Ishak K, Baptista A, Bianchi L et al.(1995): “Histological grading and staging of chronic hepatitis,” *Journal of Hepatology*, 22, 6, 696–699,.

102-Ishak K, Baptista A, Bianchi L, et al.(1995): Histological grading and staging of chronic hepatitis. *J Hepatol*,22: 696–9.

103-Jensen DM, Morgan TR, Marcellin P, et al.(2006): Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. *Hepatology*,43: 954–60.

104-Kamal S.(2009): Hepatitis C genotype 4 therapy: increasing options and improving outcomes. *Liver Int*, 29(Suppl.1): 39–48.

105-Kamal SM, El Kamary SS, Shardell MD, Hashem M, Ahmed IN, Muhammadi M, Sayed K, Moustafa A, Hakem SA, Ibrahiem A, Moniem M, Mansour H, Abdelaziz M.(2007): Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: The role of rapid and early virologic response. *Hepatology*. 46(6):1732-40.

106-Kamal SM, El Tawil AA, Nakano T.(2005): Peginterferon alpha-2b and ribavirin therapy in chronic hepatitis C genotype 4: impact of treatment duration and viral kinetics on sustained virological response. *Gut*, 54: 858–66.

108-Kamanna V. S., Kashyap M. L., Pai R. et al.(1994): “Uremic serum subfraction inhibits apolipoprotein A-I production by a human

hepatoma cell line,” Journal of the American Society of Nephrology, 5, no. 2, 193–200,.

109- Kamar N, Ribes D, Izopet J, Rostaing L.(2006): Treatment of hepatitis C virus infection (HCV) after renal transplantation: implications for HCV-positive dialysis awaiting a kidney transplant. Transplantation, 82: 853.

110-Kamar N, Rostaing L, Selves J, et al.(2005): Natural history of hepatitis C virus-related liver fibrosis after renal transplantation. Am J Transplant, 5: 1704.

111-Kamar N, Sandres-Saune´ K, Rostaing L.(2007): Influence of rituximab therapy on hepatitis C virus N concentration in kidney-transplant patients. Am J Translant, 7: 2440.

112-Kamar N, Toupamce O, Buchler M, et al.(2003): Evidence that clearance of hepatitis C virus RNA alter alpha interferon therapy in dialysis patients is sustained alter renal transplantation. J Am Soc Nephrol, 14: 2092.

113-Kamar N., Rostaing L., Sandres K., Ribes D., Durand D. (2004) : and Izopet J. (2004): Amantadine therapy in renal transplant patients with hepatitis C virus infection. Journal of Clinical Virology 30 110–114.

- 114- Kanda, T., Basu, A., Steele, R., Wakita, T., Ryerse, J. S., Ray, R. and Ray, R. B. (2006):** Generation of infectious hepatitis C virus in immortalized human hepatocytes. *J. Virol.* 80, 4633–4639
- 115- Kasuno K, Ono T, Matsumori A, et al.(2003):** Hepatitis c virus associated tubulo-interstitial injury. *Am J Kidney Dis*,41: 767.
- 116- Kawaguchi T, Yoshida T, Harada M, et al.(2004):** Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling 3. *Am J Pathol*, 165: 1499–508.
- 117- KDIGO.(2009):** clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease,” *Kidney International. Supplement*, 109, S1–S99.
- 118- NIH consensus statement on management of hepatitis C: (2002)”** *NIH Consens State Sci Statements*, 19, 3, 1–46, 2002.
- 119- KDIGO.(2008)** Clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. *Kidney Int*,73(Suppl. 109): S1.
- 120-Keck ZY, Machida K, Lai MM, et al.(2008):** Therapeutic control of hepatitis C virus: the role of neutralizing monoclonal antibodies. *Curr Top Microbiol Immunol* , 317 : 1 -38

121-Khattab M, Emad M, Abdelaleem A, et al.(2009): Pioglitazone improves virological response to peginterferon a-2b/ribavirin combination therapy in hepatitis C genotype 4 patients with insulin resistance. *Liver Int*, 30: 447–54.

122-Kolykhalov, A. A., Feinstone, S. M. and Rice, C. M. (1996): Identification of a highly conserved sequence element at the 3_ terminus of hepatitis C virus genome RNA. *J. Virol.* 70, 3363–3371

123-Koshy A, Marcellin P, Martinot M, Madda JP.(2000): Improved response to ribavirin interferon combination compared with interferon alone in patients with type 4 chronic hepatitis C without cirrhosis. *Liver*,20: 335–9.

124- Kwo P, Lawitz E, McCone E, et al.(2008): Interim results from HCV SPRINT-1: RVR/EVR from Phase 2 study of boceprevir plus pegintron TM (peginterferon alfa-2B)/ribavirin in treatment-naive subjects with genotype-1 CHC. *J Hepatol* ; 48 (Suppl 2): S372

125- Kwo PY, Lawitz EJ, McCone J, Schiff ER, Vierling JM, Pound D, Davis MN, Galati JS, Gordon SC, Ravendhran N, 125- Rossaro L, Anderson FH, Jacobson IM, Rubin R, Koury K, Pedicone LD, Brass CA, Chaudhri E, Albrecht JK; SPRINT-1 investigators. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naïve patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. *Lancet.* 2010 Aug 28;376(9742):705-16.

126 - Lang L.(2007): Interim results presented at EASL from PROVE 1 clinical trial of investigational drug telaprevir in patients with genotype 1 hepatitis C. *Gastroenterology* 132 : 2283 -4

127- Lauer GM and B. D.(2001): Walker, “Hepatitis C virus infection,” *New England Journal of Medicine*, vol. 345, no. 1, pp. 41–52,.

128 - Lawitz E, Rodriguez-Torres M, Muir AJ, et al.(2008): Antiviral effects and safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis C patients. *J Hepatol* ; 49 : 163 -9

129- Legrand-Abravanel F(2009): Colson P, Leguillou-Guillemette H, Alric L, Ravaux I, Lunel-Fabiani F, Bouviers-Alias M, Trimoulet P, Chaix ML, Hézode C, Foucher J, Fontaine H, Roque-Afonso AM, Gassin M, Schvoerer E, Gaudy C, Roche B, Doffoël M, D'Alteroche L, Vallet S, Baazia Y, Pozzetto B, Thibault V, Nousbaum JB, Roulot D, Coppere H, Poynard T, Payan C, Izopet J. Influence of the HCV subtype on the virological response to pegylated interferon and ribavirin therapy. *J Med Virol*. 81(12):2029-35.

130- Lesburg, C. A., Cable, M. B., Ferrari, E., Hong, Z., Mannarino, A. F. and Weber, P. C. (1999) Crystal structure of the RNA-dependent RNA polymerase from hepatitis C virus reveals a fully encircled active site. *Nat. Struct. Biol.* 6, 937–943

131- Lin E, Hwang Y, Wang SC, et al.(2006): An artificial neural network approach to the drug efficacy of interferon treatments. *Pharmacogenomics*, 7: 1017–24.

132- Liu C. H., C. Liang C., Liu C. J. et al.(2010): “The ratio of aminotransferase to platelets is a useful index for predicting hepatic fibrosis in hemodialysis patients with chronic hepatitis C,” *Kidney International*, 78, 1, 103–109,.

133- Liu CH, Liang CC, Lin JW, et al.(2008): Pegylated interferon alpha-2a versus standard interferon alpha-2a for treatment-naive dialysis patients with chronic hepatitis C: a randomised study. *Gut*, 57: 525.

134 - Lohmann, V., Korner, F., Koch, J., Herian, U., Theilmann, L. and Bartenschlager, R. (1999): Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. *Science* 285, 110–113

135 - Love, R. A., Parge, H. E., Wickersham, J. A., Hostomsky, Z., Habuka, N., Moomaw, E.W., Adachi, T. and Hostomska, Z. (1996): The crystal structure of hepatitis C virus NS3 proteinase reveals a trypsin-like fold and a structural zinc binding site. *Cell* 87, 331–342

136- Luan FL, Schaubel DE, Zhang H, Jia X, Pelletier SJ, Port FK, et al.(2008): Impact of immunosuppressive regimen on

survival of kidney transplant recipients with hepatitis C. *Transplantation*,85(11):1601-6.

137- Males S, Gad RR, Esmat G, Abobakr H, Anwar M, Rekacewicz C, El Hoseiny M, Zalata K, Abdel-Hamid M, Bedossa P, Pol S, Mohamed MK, Fontanet A.(2007): Serum alpha-foetoprotein level predicts treatment outcome in chronic hepatitis C. *Antivir Ther*,12(5):797-803.

138- Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK.(2001): Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. *Lancet*. 22;358(9286):958-65.

139- Marcello T, Grakoui A, Barba-Spaeth G, et al.(2006): Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. *Gastroenterology*, 131: 1887–98.

140- Markowitz GS, Cheng JT, Colvin RB, et al.(1998): Hepatitis C viral infection is associated with fibrillary glomerulonephritis and immunotactoid glomerulopathy. *J Am Soc Nephrol*, 9: 2244.

141- Martin P., Carter D., Fabrizi F. et al.(2000): “Histopathological features of hepatitis C in renal transplant candidates,” *Transplantation*, 69, 7, 1479–1484.

142- Martinot-Peignoux M, Maylin S, Moucari R, et al.(2009):
Virological response at 4 weeks to predict outcome of hepatitis C treatment with pegylated interferon and ribavirin. *Antivir Ther*,14: 501–11.

143- Maylin S, Martinot-Peignoux M, Moucari R, et al.(2008):
Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C. *Gastroenterology*, 135: 821–9.

144- Maylin S, Martinot-Peignoux M, Ripault MP, et al.(2009):
Sustained virological response is associated with clearance of hepatitis C virus RNA and a decrease in hepatitis C virus antibody. *Liver Int*, 29: 511–7.

145 -McCown MF, Rajyaguru S, Le Pogam S, et al.(2008): The hepatitis C virus replicon presents a higher barrier to resistance to nucleoside analogs than to nonnucleoside polymerase or protease inhibitors. *Antimicrob Agents Chemother* , 52 : 1604 -12

146 - McHutchison JG, Everson GT, Gordon SC, et al.(2008):
PROVE 1: Results from a Phase 2 study of telaprevir with peginterferon alpha-2a and ribavirin in treatment-naïve subjects with hepatitis C. *J Hepatol* , 48 (Suppl 2): S4

147- McHutchison JG, Gordon SC, Schiff ER, et al.(1998):
Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. *N Engl J Med*, 339: 1485–92.

148 - McHutchison JG, Poynard T.(1999): Combination therapy with interferon plus ribavirin for the initial treatment of chronic hepatitis C. *Semin Liver Dis*, 19 Suppl 1:57-65.

149- Melian EB, Plosker GL.(2001): Interferon alfacon-1: a review of its pharmacology and therapeutic efficacy in the treatment of chronic hepatitis C. *Drugs* , 61 : 1661 -91

150- Mihm U, Herrmann E, Sarrazin C, Zeuzem S.(2006): Review article: predicting response in hepatitis C virus therapy. *Aliment Pharmacol Ther.* 15;23(8):1043-54.

151 - Miller FD, Abu-Raddad LJ.(2010): Evidence of intense ongoing endemic transmission of hepatitis C virus in Egypt. *Proc Natl Acad Sci U S A*, 17;107(33):14757-62.

152 - Mohamed MK, Hussein MH, Massoud AA, et al.(1996): Study of the risk factors for viral hepatitis C infection among Egyptians applying for work abroad. *J Egypt Public Health Assoc*,71 (1-2):113-47.

153 - Morales JM, Campistol JM, Castellano G, et al.(1995): Transplantation of kidneys from donors with hepatitis C antibody into recipients with pre-transplantation anti-HCV. *Kidney Int*, 47: 236.

153 - Morales JM, Campistol JM.(2000): Transplantation in the patient with hepatitis C. *J Am Soc Nephrol*; 11: 1343.

154- Morales JM, Morales E, Andres A, Praga M.(1999): Glomerulonephritis associated with hepatitis C virus infection. Curr Opin Nephrol Hypertens 8: 205.

155 - Morales JM, Pascual J, Campistol JM, et al.(1997): Membranous glomerulonephritis associated with hepatitis virus infection in renal transplant patients. Transplantation, 63: 1634.

156 - Moreso F, Ibernón M, Goma M, et al.(2006): Subclinical rejection associated with chronic allograft nephropathy in protocol biopsies as a risk factor for late graft loss. Am J Transplant, 6: 747.

157 - Moucari R, Asselah T, Cazals-Hatem D, et al.(2008): Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis. Gastroenterology, 134: 416–23.

158 - Muñoz de Bustillo E, Ibarrola C, Colina F, et al.(1998): Fibrosing cholestatic hepatitis in hepatitis C virus-infected transplant recipients. J Am Soc Nephrol, 9: 1109.

159 - Muñoz de Rueda P, Casado J, Paton R, et al.(2008): Mutations in E2-PePHD, NS5A-PKRBD, NS5A-ISDR, and NS5A-V3 of hepatitis C virus genotype 1 and their relationships to pegylated interferon-ribavirin treatment responses. J Virol, 82: 6644–53.

160 - Nicot F, Alric L, Barange K, Métivier S, Dramard JM, Combis JM, Castan B, Meurisse JJ, Payen JL, Garipuy D, Desmorat H, Peron JM, Thebault S, Morin T, Renou C, Barel P, Guerin B, Imbert Y, Sire S, Sauné K, Chatelut E, Izopet J.(2011): Influence of HCV genotype 1 subtypes on the virus response to PEG interferon alpha-2a plus ribavirin therapy. J Med Virol. ,83(3):437-44.

161- Novelli G., Rossi M., Ferretti G., Poli L., Pretagostini R., Ruberto F., Morabito V. and Cinti P. (2009):Adacolumn Treatment in Kidney Transplant Patients With Hepatitis C Virus. Transplantation Proceedings, 41, 1195–1200.

162 - Osborn BL, Olsen HS, Nardelli B, et al.(2002): Pharmacokinetic and pharmacodynamic studies of a human serum albumin-interferon-alpha fusion protein in cynomolgus monkeys. J Pharmacol Exp Ther , 303 : 540 -48.

163 - Pageaux GP, Hilleret MN, Garrigues V, et al.(2009): Pegylated interferon-alpha-based treatment for chronic hepatitis C in renal transplant recipients: an open pilot study. Transplant Int,22: 562.

164- Paradis V, Asselah T, Dargere D, et al.(2006): Serum proteome to predict virologic response in patients with hepatitis C treated by pegylated interferon plus ribavirin. Gastroenterology, 130: 2189–97.

165- Parfieniuk A, Jaroszewicz J, Flisiak R.(2007): Specifically targeted antiviral therapy for hepatitis C virus. *World J Gastroenterol*, 13: 5673-5681.

166 - Pattullo V, Ravindran NC, Mazzulli T, Wong DK, Heathcote EJ.(2010) : Pegylated interferon plus optimized weight-based ribavirin dosing negate the influence of weight and body mass index on early viral kinetics and sustained virological response in chronic hepatitis C. *J Viral Hepat*,17(12):834-8.

167 - Pawa S., Ehrinpreis M., Mutchnick M., Janisse J., Dhar R., and Siddiqui F. A.(2007): “Percutaneous liver biopsy is safe in chronic hepatitis C patients with end-stage renal disease,” *Clinical Gastroenterology and Hepatology*, 5, 11, 1316–1320.

168 - Pawlotsky JM, Chevaliez S, McHutchison JG.(2007): The hepatitis C virus life cycle as a target for new antiviral therapies. *Gastroenterology* ,132 : 1979 -98

169 - Pazienza V, Clement S, Pugnale P, et al.(2007): The hepatitis C virus core protein of genotypes 3a and 1b downregulates insulin receptor substrate 1 through genotype-specific mechanisms. *Hepatology*, 45: 1164–71.

170 - Penin F, Dubuisson J, Rey FA, et al.(2004): Structural biology of hepatitis C virus. *Hepatology* , 39 : 5 -19.

171- *Pereira BJ, Levey A.(1993):* Hepatitis C in organ transplantation: its significance and influence on transplantation policies. *Curr Opin Nephrol Hypertens*; 2: 912.

172 - *Pereira BJ, Levey AS.(1997):* Hepatitis C virus infection in dialysis and renal transplantation. *Kidney Int*, 51: 981.

173 - *Pereira BJ, Levey AS.(1997):* Hepatitis C virus infection in dialysis and renal transplantation. *Kidney Int*, 51: 981.

174 - *Pereira BJG.(1997):* and Levey AS, “Hepatitis C virus infection in dialysis and renal transplantation,” *Kidney International*, 51, 4, 981–999.

175- *Perez RM, Ferreira AS, Medina-Pestana JO, et al.(2006):* Is hepatitis C more aggressive in renal transplant patients than in patients with end-stage renal disease? *J Clin Gastroenterol*, 40: 444.

176- *Perico N, Cattaneo D, Bikbov B, et al.(2009):* Hepatitis infection and chronic renal diseases. *Clin J Am Soc Nephrol*, 4: 207.

177 - *Pockros PJ, Jeffers L, Afdhal N, et al.(2007):* Final results of a double-blind, placebo-controlled trial of the antifibrotic efficacy of interferon-gamma1b in chronic hepatitis C patients with advanced fibrosis or cirrhosis. *Hepatology* , 45 : 569 -78

178 - Pockros PJ, Nelson D, Godofsky E, et al.(2008): R1626 plus peginterferon alfa-2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin. *Hepatology*, 48 : 385 -97

179- Poordad F, Lawitz E, Shiffman ML, Hassanein T, Muir AJ, Bacon BR, Heise J, Halliman D, Chun E, Hammond J.(2010): Virologic response rates of weight-based taribavirin versus ribavirin in treatment-naïve patients with genotype 1 chronic hepatitis C. *Hepatology*. 52(4):1208-15.

180 - Poynard T, Colombo M, Bruix J, et al.(2009): Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy. *Gastroenterology*, 136: 1618–28.

181 - Poynard T, Ratziu V, Charlotte F, Goodman Z J. McHutchison, and J.(2001): Albrecht, “Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C,” *Journal of Hepatology*, 34, 5, 730–739.

182- Poynard T., Imbert-Bismut F., Ratziu V. et al.(2002): “Biochemical markers of liver fibrosis in patients infected by hepatitis C virus: longitudinal validation in a randomized trial,” *Journal of Viral Hepatitis*, 9, 2, 128–133.

183- Randall G, Chen L, Panis M, et al.(2006): Silencing of USP18 potentiates the antiviral activity of interferon against hepatitis C virus infection. *Gastroenterology*131: 1584–91.

184- Rauch A, Kutalik Z, Descombes P, et al.(2010): Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure – A Genome-Wide Association Study. *Gastroenterology*, 138: 1338–45.

185- Rendina M, Schena A, Castellaneta NM, et al.(2007): The treatment of chronic hepatitis C with peg-interferon alfa-2a (40 kDa) plus ribavirin in haemodialysed patients awaiting renal transplant. *J Hepatol*, 46: 768.

186 - Rossignol JF, Elfert A, El-Gohary Y, Keefe EB.(2009): Improved virologic response in chronic hepatitis C genotype 4 treated with nitazoxanide, peginterferon, and ribavirin. *Gastroenterology*. 136(3):856-62.

187- Rostaing L, Izopet J, Sandres K, et al.(2000): Changes in hepatitis C virus RNA viremia concentrations in long-term renal transplant patients after introduction of mycophenolate mofetil. *Transplantation*, 69: 991.

188- Roth D, Cirocco R, Zucker K, et al.(1995): De novo membranoproliferative glomerulonephritis in hepatitis C virus infected renal allografts recipients. *Transplantation*,59: 1676.

189- Roth D, Zucker K, Cirocco R, et al.(1996): A prospective study of hepatitis C virus infection in renal allograft recipients. Transplantation 61: 886.

190- Roth D.(1995): Hepatitis C virus: the nephrologist's view. Am J Kidney Dis, 25: 3.

191- Roth D., Zucker K., Cirocco R. et al.(1994): "The impact of hepatitis C virus infection on renal allograft recipients," Kidney International, 45, 1, 238–244.

192 - Russo MW, Goldsweig CD, Jacobson IM, Brown Jr RS.(2003): Interferon monotherapy for dialysis patients with chronic hepatitis C: an analysis of the literature on efficacy and safety. Am J Gastroenterol, 98: 1610.

193- Sabharwal S, Delgado-Borrego A, Chung RT.(2008): Extrahepatic hepatitis C virus after transplantation: diabetes and renal dysfunction. Liver Transpl, 14: S51.

194- Sabovic M., Salobir B., Zupan I.(2006): Bratina P., Bojec P., V., and J. Ponikvar B., "The influence of the haemodialysis procedure on platelets, coagulation and fibrinolysis," Pathophysiology of Haemostasis and Thrombosis, 34, 6, 274–278.

195- Sansonno D, Lauletta G, Montrone M, et al.(2005): Hepatitis C virus RNA and core protein in kidney glomerular and tubular structures isolated with laser microdissection. Clin Exper Immunology,140: 498.

196 - Sarrazin C, Rouzier R, Wagner F, et al.(2007): SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders. Gastroenterology, 132 : 1270 -8.

197 - Savas N., Ocal S., Colak T., Karakayali H., Yilmaz U. and Haberal M. (2007): Clinical Course of Hepatitis C Virus Infection in Renal Transplant Recipients. Transplantation Proceedings, 39, 984–986.

198 - Schiavon L. L., J. Schiavon L. N., Carvalho Filho R. J. et al.(2007): “Simple blood tests as noninvasive markers of liver fibrosis in hemodialysis patients with chronic hepatitis C virus infection,” Hepatology, 46, 2, 307–314.

199- Schussler T, Staffeld-Coit C, Eason J, Nair S.(2004): Severe hepatitis C infection in a renal transplant recipient following hepatitis C genotype mismatch transplant. Am J Transplant,4: 1375.

200- Scott D. R., Wong J. K., T. S. Spicer et al.(2010): “Adverse impact of hepatitis C virus infection on renal replacement therapy

and renal transplant patients in Australia and New Zealand,”
Transplantation, 90, 11, 1165–1171.

201- Scott DR, Wong JK, Spicer TS et al.(2010): “Adverse impact of hepatitis C virus infection on renal replacement therapy and renal transplant patients in Australia and New Zealand,” Transplantation, 90, 11, 1165–1171.

202- Sheppard P, Kindsvogel W, Xu W, et al.(2003): IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol, 4: 63–8.

203- Shiffman M, Berg T, Poordad F, et al. (2008): A study of telaprevir combined with peginterferon-alfa 2a and ribavirin in subjects with well-documented non-response or relapse after previous peginterferon-alfa 2a and ribavirin treatment: Interim analysis. 59th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). San Francisco, USA. October 31–4.

204- Sobesky R, Mathurin P, Charlotte F, Moussalli J, Olivi M, Vidaud M, et al.(1999): Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: a dynamic view. The Multivirc Group. Gastroenterology,116:378-386.

205- Specht CS, Lewin-Smith MR, Kalasinsky VF, Peterson MR, Mullick FG.(2000): The surgical pathology and cytopathology of US Persian Gulf War military veterans. Arch Pathol Lab Med,124(9):1299-301.

206- Strader DB, Wright T, Thomas DL, Seeff LB.(2004): Diagnosis, management, and treatment of hepatitis C. *Hepatology*,39:1147-1171.

207 - Suppiah V, Moldovan M, Ahlenstiel G, et al.(2009): IL28B is associated with response to chronic hepatitis C interferonalpha and ribavirin therapy. *Nat Genet*, 41: 1100–4.

208- Tanaka Y, Nishida N, Sugiyama M, et al.(2009): Genome-wide association of IL28B with response to pegylated interferonalpha and ribavirin therapy for chronic hepatitis C. *Nat Genet*, 41: 1105–9.

209 - Tesi RJ, Waller K, Morgan CJ, et al.(1994): Transmission of hepatitis C by kidney transplantation: the risks. *Transplantation*, 57: 826.

210- Thomas DL, Thio CL, Martin MP, et al.(2009): Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. *Nature*, 461: 798–801.

211 - Torres J, Aguado JM, San Juan R, et al.(2008): Hepatitis C virus, an important risk factor for tuberculosis in immunocompromised: experience with kidney transplantation. *Transplant Int*, 21: 873.

212- Torres-Puente M, Cuevas JM, Jimenez-Hernandez N, et al.(2008): Hepatitis C virus and the controversial role of the interferon

sensitivity determining region in the response to interferon treatment. J Med Virol, 80: 247–53.

213- Varaut A., Fontaine H., Serpaggi J. et al.(2005): “Diagnostic accuracy of the fibrotest in hemodialysis and renal transplant patients with chronic hepatitis C virus,” Transplantation, 80, 11, 1550–1555.

214 - Veldt BJ, Heathcote EJ, Wedemeyer H, Reichen J, Hofmann WP, Zeuzem S, et al.(2007): Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med,147:677-684.

215- Veroux P, Veroux M, Sparacino V, et al.(2006): Kidney transplantation from donors with viral B and C hepatitis. Transplant Proc, 38: 996.

216- Vezali E, Aghemo A, Colombo M.(2011): Interferon in the treatment of chronic hepatitis C: a drug caught between past and future. Expert Opin Biol Ther ,11(3):301-13.

217- von Wagner M, Huber M, Berg T, et al.(2005): Peginterferonalpha- 2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology, 129: 522–7.

218- Vosnides GG.(1997): Hepatitis C in renal transplantation. Kidney Int, 52: 843.

219- Vosnides GG.(1997): Hepatitis C in renal transplantation. Kidney Int, 52: 843.

220- Watashi K, Hijikata M, Hosaka M, et al. (2003):Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. Hepatology, 38: 1282.

221- Weclawiack H, Kamar N, Mehrenberger M, et al.(2008): Alpha-interferon therapy for chronic hepatitis C may induce acute allograft rejection in kidney transplant patients with failed allografts. Nephrol Dial Transplant, 23: 1043.

222- Weclawiack H, Kamar N, Mehrenberger M, et al.(2008): Alpha-interferon therapy for chronic hepatitis C may induce acute allograft rejection in kidney transplant patients with failed allografts. Nephrol Dial Transplant, 23: 1043.

223- Wen CP, Cheng TY, Tsai MK. et al.(2008): “All-cause mortality attributable to chronic kidney disease: a prospective cohort study based on 462 293 adults in Taiwan,” The Lancet, 371, 9631, 2173–2182.

224 - Witthoeft T, Fuchs M, Ludwig D.(2007): Recent i.v.-drug users with chronic hepatitis C can be efficiently treated with daily high dose induction therapy using consensus interferon: an open-label pilot study. World J Gastroenterol ,13 : 579 -84

225- Wornle M, Schmid H, Banas B, et al.(2006): Novel role of toll-like receptor 3 in hepatitis C-associated glomerulonephritis. Am J Pathol, 168: 370.

226 - Yanagi, M., Purcell, R. H., Emerson, S. U. and Bukh, J. (1997): Transcripts from a single full-length cDNA clone of hepatitis C virus are infectious when directly transfected into the liver of a chimpanzee. Proc. Natl. Acad. Sci. U.S.A. 94, 8738–8743

227 - Younossi ZM, Baranova A, Afendy A, et al.(2009): Early gene expression profiles of patients with chronic hepatitis C treated with pegylated interferon-alfa and ribavirin. Hepatology,49: 763–74.

228-Younossi ZM, McCullough AJ.(2009): Metabolic syndrome, nonalcoholic fatty liver disease and hepatitis C virus: impact on disease progression and treatment response. Liver Int, 29: 3–12.

229- Youssef A, Yano Y, Utsumi T, et al.(2009): Molecular epidemiological study of hepatitis viruses in Ismailia, Egypt. Intervirology,52(3):123-31.

130- Zeuzem S, Buti M, Ferenci P, et al.(2006): Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol, 44: 97–103.

131- Zeuzem S, Sarrazin C, Wagner F, et al.(2005): Combination therapy with the HCV protease inhibitor SCH 503034, plus peg-Intron in hepatitis C genotype-1 peg-Intron nonresponders: phase 1 b results. Hepatology , 42 (Suppl 1): 276A

132- Zhong, J., Gastaminza, P., Cheng, G., Kapadia, S., Kato, T., Burton, D. R., Wieland, S. F., Uprichard, S. L., Wakita, T. and Chisari, F. V. (2005): Robust hepatitis C virus infection in vitro. Proc. Natl. Acad. Sci. U.S.A. 102, 9294–9299

133- Zylberberg H, Nalpas B, Carnot F, et al.(2002): Severe evolution of chronic hepatitis C in renal transplantation: a case control study. Nephrol Dial Transplant, 17: 129.